Back to search results

MEVPRO-1 Study for Metastatic Castration-Resistant Prostate Cancer

This study, called MEVPRO-1, is for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed after treatment with abiraterone acetate. It aims to see if combining a new medicine, PF-06821497, with enzalutamide is safe and effective. This combination is compared to treatment with either enzalutamide alone or docetaxel (chemotherapy). The study will enroll about 600 men aged 18 and older who have prostate cancer that has spread to bones or soft tissue. Researchers will measure how long participants live without their cancer growing or spreading, which is called radiographic progression-free survival (rPFS). The study is currently evaluating its status.

Study design
This is a randomized, open-label, multi-center study comparing different treatment combinations. It plans to enroll about 600 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, radiographic progression-free survival, will be measured from randomization up to approximately 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06551324

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
Pfizer
~600 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:PF-06821497DocetaxelEnzalutamide

At a glance

Recruiting sites
0 of 224 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
Measured over Randomization up to approximately 2 years.

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Explore related trials

Prostate Carcinoma

Where it's being run

224 sites across 111 states
Florida20
California14
Arizona7
Taiwan6
Seoul-teukbyeolsi [seoul]5
Spain5
Turkey (Türkiye)5
New York4

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required.
Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.

Exclusion

Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study.
Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
Clinically significant cardiovascular disease.
Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy, CDK4/6 inhibitors, or other systemic anti-cancer treatment, with the following exceptions:
Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer).
Inadequate organ function.

What this trial measures

  • Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)Randomization up to approximately 2 years.

    rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or in bone per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines by BICR, or death, whichever occurs first.